[go: up one dir, main page]

GB201317550D0 - Use of Enalaprilat for treatment of neurodegenerative diseases - Google Patents

Use of Enalaprilat for treatment of neurodegenerative diseases

Info

Publication number
GB201317550D0
GB201317550D0 GBGB1317550.0A GB201317550A GB201317550D0 GB 201317550 D0 GB201317550 D0 GB 201317550D0 GB 201317550 A GB201317550 A GB 201317550A GB 201317550 D0 GB201317550 D0 GB 201317550D0
Authority
GB
United Kingdom
Prior art keywords
enalaprilat
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1317550.0A
Other versions
GB2508702A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST
MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI AKADEMII NAUK IMB
RAN
Original Assignee
FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST
MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI AKADEMII NAUK IMB
RAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST, MOLEKULYARNOI BIOLOG IM V A ENGELGARDTA ROSSIISKOI AKADEMII NAUK IMB, RAN filed Critical FEDERALNOE G BYUDZHETNOE UCHREZHDENIE NAUKI INST
Publication of GB201317550D0 publication Critical patent/GB201317550D0/en
Publication of GB2508702A publication Critical patent/GB2508702A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB1317550.0A 2012-10-05 2013-10-03 Enalaprilat in the treatment of neurodegenerative diseases Withdrawn GB2508702A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2012142334/15A RU2530601C2 (en) 2012-10-05 2012-10-05 Zinc-dependent beta-amyloid dimer formation inhibitor

Publications (2)

Publication Number Publication Date
GB201317550D0 true GB201317550D0 (en) 2013-11-20
GB2508702A GB2508702A (en) 2014-06-11

Family

ID=49630167

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1317550.0A Withdrawn GB2508702A (en) 2012-10-05 2013-10-03 Enalaprilat in the treatment of neurodegenerative diseases

Country Status (4)

Country Link
DE (1) DE102013110890A1 (en)
FR (1) FR2996456A1 (en)
GB (1) GB2508702A (en)
RU (1) RU2530601C2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098889A (en) * 1990-09-17 1992-03-24 E. R. Squibb & Sons, Inc. Method for preventing or inhibiting loss of cognitive function employing a combination of an ace inhibitor and a drug that acts at serotonin receptors
DE10125883A1 (en) * 2001-05-28 2002-12-12 Serumwerk Bernburg Ag Medicines containing an effector of glutathione metabolism together with alpha-lipoic acid in the context of kidney replacement therapy
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
DE10303229B4 (en) * 2003-01-28 2007-07-26 Keyneurotek Ag Ambroxol and Angiotensin Converting Enzyme (ACE) inhibitors Drugs and their use in the treatment of neurodegenerative diseases
JPWO2005011736A1 (en) * 2003-07-30 2006-09-14 株式会社 東北テクノアーチ Preventive and / or therapeutic agent for Alzheimer's disease

Also Published As

Publication number Publication date
DE102013110890A1 (en) 2014-04-10
GB2508702A (en) 2014-06-11
RU2530601C2 (en) 2014-10-10
FR2996456A1 (en) 2014-04-11
RU2012142334A (en) 2014-04-10

Similar Documents

Publication Publication Date Title
IL239368A0 (en) Ppar-sparing thiazolidiones and combinations for the treatment of neurodegenerative diseases
IL238464A0 (en) Agents for treatment of claudin expressing cancer diseases
IL231678A (en) 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
SMT201800380T1 (en) Combination therapy for treatment of multiple sclerosis
EP2906583A4 (en) Peptides for the treatment of neurodegenerative diseases
IL234813A0 (en) Methods for increasing efficacy of cd37-based therapy
HUE039650T2 (en) System for medical treatment
IL239273A0 (en) Method for treatment of diseases
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
ZA201308176B (en) Therapeutic treatment
IL225624A0 (en) Prophyrin treatment of neurodegenerative diseases
GB201317550D0 (en) Use of Enalaprilat for treatment of neurodegenerative diseases
GB201204645D0 (en) Treatment of disease
GB201208505D0 (en) Treatment of skin condition
GB201101183D0 (en) Treatment of neurodegenerative disorders

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)